May 29 2015
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"), a clinical-stage biopharmaceutical company principally focused on the development of targeted therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the LD Micro Invitational being held June 1-3, 2015, at the Luxe Sunset Boulevard, Los Angeles, CA.
As part of his presentation, Roelof Rongen, President and Chief Executive Officer at Matinas BioPharma, will discuss the topline results from the pharmacokinetic and pharmacodynamic study of the Company's cardiovascular and metabolic product candidate MAT9001 on Tuesday, June 2, 2015, at 3:00 p.m. PDT / 6:00 p.m. EDT. Mr. Rongen will also review the clinical development strategy for MAT2203, a novel lipid-crystal nano-particle orally delivered formulation of Amphotericin B for the treatment of invasive fungal infections, and MAT2501, an early-stage program to treat gram-negative bacterial infections using an orally available formulation of Amikacin, a broad spectrum aminoglycoside.
A live webcast of the presentation will be available on the Events page of the Investor Relations section of the Company's website (www.matinasbiopharma.com). A webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.
About the LD Micro Invitational
LD Micro is an internet-based financial newsletter firm that provides self-directed investors information on selected public companies that in the opinion of LD Micro have great investment potential. The Invitational has grown from a small gathering five years ago, to one of the pre-eminent events in the micro-cap space. The firm also hosts the LD Micro Main Event in December. LD Micro is a non-registered investment advisor. For more information, please visit www.ldmicro.com.
About MAT9001
MAT9001 is a proprietary prescription-only omega-3 fatty acid-based composition, comprising docosapentaenoic acid (DPA) and other omega-3 fatty acids, which is under development for therapeutic applications with severe hypertriglyceridemia (TG>500 mg/dL) as the lead indication. Promising pre-clinical studies with DPA and MAT9001 indicate distinctive therapeutic response properties. In the fourth quarter of 2014, Matinas BioPharma filed an IND for MAT9001 with FDA. The Company believes that its development program and related clinical investigations may yield an improved therapeutic profile compared to existing therapies, based on MAT9001's differentiating mechanistic features associated with its unique composition.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical company with a principal focus on identifying and developing novel and targeted pharmaceutical products for the treatment of various infectious diseases, with additional programs developing therapies to treat cardiovascular and metabolic conditions. Led by an experienced management team and a board of directors with a history of building pharmaceutical companies, Matinas BioPharma is focused on creating highly differentiated, safe and efficacious therapies utilizing its expertise in drug formulation and development in order to address significant unmet medical needs. Matinas BioPharma's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.